A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants

Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs HIV clades A C B DNA vaccine Inovio (Primary) ; HIV clades A C B DNA vaccine Inovio (Primary) ; Interleukin-12; Interleukin-12
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 According to an Inovio Pharmaceuticals media release, data from this study was presented at a plenary session at the 2017 HVTN Spring Full Group Meeting.
    • 24 May 2017 Results published in the Inovio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top